RECRUITING

Mechanisms of Pregnancy Vascular Adaptations

Talk to us

Conditions

Pre-EclampsiaVascular Diseases

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators will collect omental tissue (research surgical excision) and placental tissue (standard of care clinical delivery) from both preeclamptic and non-preeclamptic women during their c-section and use these samples to study the blood vessels, specifically the expression/activation of the AT2R.

Official Title

Angiotensin 2 Receptor (AT2R) Expression/Activation in Endothelial Cells in Preeclampsia

Quick Facts

Study Start:2018-11-20
Study Completion:2027-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03806283

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 40 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * female
  2. * Minimum age: 18
  3. * Maximum age: 40
  4. * Singleton births
  5. * Minimum gestational age at consent: 28 weeks, 0 days
  6. * Maximum gestational age at consent: 41 weeks, 0 days
  7. * Undergoing caesarean section, either planned or otherwise with or without trial of labor
  1. * Preexisting hypertension treated by antihypertensive agents during the prenatal period. This will not include treatment of severe hypertension by antihypertensive or use of magnesium sulfate after the patient is hospitalized for the diagnosis of preeclampsia.
  2. * Any major fetal structural anomalies or aneuploidies
  3. * Preexisting conditions like pre-gestational type I or type II diabetes mellitus, pre-pregnancy kidney disease with increased serum creatinine above 1.2 mg/dL, or other underlying blood vessel problems like systemic lupus erythematosus or other autoimmune conditions with evidence of pre-pregnancy proteinuria or hypertension.
  4. * Undergoing cesarean section for placental abruption or bleeding complications.
  5. * Singleton gestation not within 36 weeks, 0 days and 41 weeks, 0 days gestational age at the time of enrollment (delivery)

Contacts and Locations

Study Contact

Sharon E Blohowiak, MS
CONTACT
6084176957
sblohowiak@wisc.edu
Rosalina Boeldt
CONTACT
608-417-4232
villalonland@wisc.edu

Principal Investigator

Sathish Kumar, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

UnityPoint Health-Meriter Hospital
Madison, Wisconsin, 53715
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Sathish Kumar, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-11-20
Study Completion Date2027-04

Study Record Updates

Study Start Date2018-11-20
Study Completion Date2027-04

Terms related to this study

Additional Relevant MeSH Terms

  • Pre-Eclampsia
  • Vascular Diseases